Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Clopidogrel brand name?

See the DrugPatentWatch profile for Clopidogrel

What brand name is clopidogrel sold under?

Clopidogrel is sold under the brand name Plavix in many countries. [1]

Are there other brand names besides Plavix?

Brand names can vary by country and manufacturer, but “Plavix” is the best-known brand name associated with clopidogrel. [1]

Is clopidogrel the same thing as Plavix?

Yes. Plavix is clopidogrel’s brand name; the active ingredient is clopidogrel. [1]

What’s the generic vs brand name difference?

“Clopidogrel” is the generic name, while “Plavix” is the brand name for that same medication. [1]

Sources

1



Other Questions About Clopidogrel :

clopidogrel bisulfate cost Drug clopidogrel 75 mg? Clopidogrel 75 mg tablet cost? Cost of clopidogrel 75 mg? Clopidogrel production cost? Clopidogrel bisulfate api? Clopidogrel cost?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Aligned

Patient Risk: Low

Summary

The claim exactly matches the boxed warning guidance to consider an alternative platelet P2Y12 inhibitor in CYP2C19 poor metabolizers due to diminished clopidogrel antiplatelet activity.


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

Use/Consider an alternative platelet P2Y12 inhibitor in patients who are CYP2C19 poor metabolizers to address diminished clopidogrel antiplatelet activity.
BOXED WARNING: states clopidogrel has reduced antiplatelet effect in patients homozygous for nonfunctional CYP2C19 alleles (CYP2C19 poor metabolizers) and: "Consider use of another platelet P2Y12 inhibitor" in these patients. Also supported by Section 5.1 (impaired CYP2C19 function/genetic variations) and Section 12.5 (diminished active metabolite exposure and platelet aggregation inhibition in poor metabolizers).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The recommendation is directly stated in the boxed warning for CYP2C19 poor metabolizers.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Aligned

Primary Issue

Suggested Improvement